EFFICACY AND SAFETY EVALUATION OF TRIFLURIDINE/TIPIRACIL FOR METASTATIC COLORECTAL CANCER (mCRC).

S. GUIJARRO HERRERA[1], S. CANO DOMÍNGUEZ[1], R. GARCÍA FUMERO[1], F. ARTIME RODRÍGUEZ-HERMIDA[1], C. VALENCIA SOTO[2], L. GUTIÉRREZ ZÚÑIGA[1], A. JIMÉNEZ MORALES[1], C. COLLADO GARCÍA[1].[1]HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES, HOSPITAL PHARMACY, GRANADA, SPAIN. [2]HOSPITAL LA INMACULADA, HOSPITAL PHARMACY, Almería, SPAIN.

Background:

Trifluridine/tipiracile is the second oral treatment approved for patients with mCRC who have received fluoropyrimidine, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biologic therapy and, if RAS wild type, an anti-EGFR

Purpose

To evaluate the efficacy and safety of patients treated with trifluridine plus tipiracil in a tertiary hospital in real world data.

Material and methods

-Retrospective descriptive observational.
-We included all patients from April 2016 to September 2017.
- Response evaluation was performed according to RECIST 1.1, and toxicity evaluation as defined by the NCI-CTCAE, version 4.0.

Results



mean: 64,2 ys

30 patients

- 19 Patients were evaluated
  - **Regarding effectiveness, the median PFS in 19 patients was 3 months**
- 3 patients continue treatment with a PFS of 3 months .
- 4 patients were awaiting PET scan evaluation
- 4 Patients were not evaluated
  - 1 was a case of *exitus.*
  - 3 due to clinical progression

53,3% KRAS wild-type

ECOG performance status: 0 -> 15 patients

Prior lines of treatment (median): 3

Number of cycles administered (median): 3



Adverse Events

33,3% required a dose reduction

Conclusion:

Effectiveness evaluation revealed a much longer PFS during routine clinical practice in comparison to the result reported in the pivotal trials (3 *versus* 2 months in RECOURSE study). Differences in study sample, number of prior lines of treatment and/or re-treatment rate may explain this fact. The safety profile, in contrast, was similar to that described in the data sheet.

More experience in the use of trifluridine/tiparacile is needed to confirm these great data.